The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

NCT ID: NCT00002357

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 144 participants
• Study Classification: INTERVENTIONAL

Brief Summary

To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone.

PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.

Detailed Description

Patients are randomized to receive one of three doses of HBY 097 with or without AZT or AZT alone for 12 weeks (AZT monotherapy arm eliminated per 1/19/96 amendment). All patients at a given dose level of HBY 097 must be enrolled and adequate safety data obtained before escalation in subsequent patients begins. Additional patients are entered at the optimal dose of HBY 097. Patients are evaluated weekly for the first 4 weeks and then every 2 weeks for the next 9 weeks.

PER AMENDMENT: Enrollment to the lowest dose cohort is completed.

Conditions

HIV Infections

Study Design

• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

HBY 097

Intervention Type: DRUG

Zidovudine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• Treatment for opportunistic infection that develops on study.

Recommended:

• PCP prophylaxis if CD4 count falls below 200 cells/mm3.

Patients must have:

• HIV infection.
• CD4 count 200 - 500 cells/mm3.
• HIV-1 RNA PCR value of 10000 copies/ml or higher.
• Asymptomatic or mildly symptomatic disease.
• No past or current AIDS-defining event.
• Consent of parent or guardian if less than legal age of consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Endocrine, hepatic, renal, or gastrointestinal disease.
• Cardiovascular conduction disease.
• Concomitant medical illness that may complicate study conduct or interpretation of results.
• Other factors that may interfere with patient compliance.

Concurrent Medication:

Excluded:

• Antiretroviral agents other than study drugs.
• Oral contraceptives.
• Cytotoxic chemotherapy.
• Immunomodulators.
• Antiproliferative agents.
• Corticosteroids.
• Anabolic steroids.
• Estrogens.
• Quinoxaline derivatives.

Concurrent Treatment:

Excluded:

• Radiation therapy.

Patients with the following prior conditions are excluded:

• History of hypersensitivity to quinoxaline derivatives or intolerance to AZT.
• History of cardiovascular conduction disease.
• Prior participation in this study or any study using HBY 097.
• Recent use of a drug that interferes with drug metabolism, absorption, distribution, or excretion.
• History of thyroid disease.

Prior Medication:

Excluded at any time:

Prior non-nucleoside reverse transcriptase inhibitors.

Excluded within 30 days prior to study entry:

• Any antiretroviral therapy.
• Oral contraceptives.
• Immunomodulating agents such as systemic corticosteroids, interleukins, or interferons.
• Cytotoxic chemotherapeutic agents.
• Other investigational drugs.

Excluded within 6 months prior to study entry:

Immunotherapeutic vaccine.

Prior Treatment:

Excluded within 30 days prior to study entry:

• Radiation therapy.
• An experimental device. Current ethanol or illicit drug abuse.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hoechst Marion Roussel

INDUSTRY

Sponsor Role: lead

Locations

Los Angeles County - USC Med Ctr

Los Angeles, California, United States

Stanford Univ School of Medicine

Stanford, California, United States

Georgetown Univ Med Ctr

Washington D.C., District of Columbia, United States

Med College of Georgia

Augusta, Georgia, United States

New York Univ Med Ctr

New York, New York, United States

Houston Clinical Research Network

Houston, Texas, United States

Countries

United States

Other Identifiers

HBY097/2001

Identifier Type: -

Identifier Source: secondary_id

252A

Identifier Type: -

Identifier Source: org_study_id